Thermo Fisher Scientific Inc. $TMO Stock Position Raised by Spirepoint Private Client LLC

Spirepoint Private Client LLC lifted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 10.9% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 12,841 shares of the medical research company’s stock after purchasing an additional 1,263 shares during the quarter. Spirepoint Private Client LLC’s holdings in Thermo Fisher Scientific were worth $7,440,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Beacon Financial Strategies CORP acquired a new position in Thermo Fisher Scientific during the 4th quarter valued at about $29,000. Olistico Wealth LLC acquired a new position in Thermo Fisher Scientific during the 4th quarter valued at about $29,000. JPL Wealth Management LLC acquired a new position in Thermo Fisher Scientific during the 3rd quarter valued at about $28,000. Highline Wealth Partners LLC boosted its stake in Thermo Fisher Scientific by 126.9% during the 3rd quarter. Highline Wealth Partners LLC now owns 59 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 33 shares during the period. Finally, Cloud Capital Management LLC acquired a new position in Thermo Fisher Scientific during the 3rd quarter valued at about $31,000. 89.23% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, EVP Gianluca Pettiti sold 400 shares of the business’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $541.20, for a total transaction of $216,480.00. Following the transaction, the executive vice president directly owned 20,752 shares of the company’s stock, valued at approximately $11,230,982.40. The trade was a 1.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the transaction, the chief executive officer directly owned 123,925 shares in the company, valued at $63,499,170. The trade was a 3.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.33% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of analysts have commented on TMO shares. Robert W. Baird set a $653.00 price target on shares of Thermo Fisher Scientific in a research report on Friday, January 30th. UBS Group restated a “neutral” rating and set a $615.00 price target on shares of Thermo Fisher Scientific in a research report on Friday, January 30th. Wells Fargo & Company set a $683.00 price target on shares of Thermo Fisher Scientific in a research report on Friday, January 30th. Weiss Ratings restated a “hold (c)” rating on shares of Thermo Fisher Scientific in a research report on Wednesday. Finally, Barclays boosted their price target on shares of Thermo Fisher Scientific from $625.00 to $650.00 and gave the stock an “overweight” rating in a research report on Friday, January 30th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $632.50.

Thermo Fisher Scientific Stock Down 0.5%

NYSE TMO opened at $500.80 on Friday. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $643.99. The company’s 50 day simple moving average is $506.97 and its 200 day simple moving average is $548.15. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.89 and a quick ratio of 1.53. The company has a market capitalization of $186.04 billion, a P/E ratio of 28.23, a PEG ratio of 2.70 and a beta of 0.97.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Thursday, January 29th. The medical research company reported $6.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.45 by $0.12. Thermo Fisher Scientific had a net margin of 15.05% and a return on equity of 16.92%. The business had revenue of $12.22 billion for the quarter, compared to analyst estimates of $11.95 billion. During the same quarter in the previous year, the business earned $6.10 earnings per share. The firm’s revenue was up 7.2% compared to the same quarter last year. Equities research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 15th. Stockholders of record on Friday, March 13th will be issued a dividend of $0.47 per share. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date is Friday, March 13th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.60%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.